Data completeness
1/8 — Limited
SEPTI-SOFT (hexachlorophene) by R-Pharm US. Approved for staphylococcal infections, hiv infections.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEPTI-SOFT is a topical hexachlorophene solution indicated for staphylococcal and HIV infections. Hexachlorophene is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and inhibits protein synthesis. This pre-launch NDA product from R-Pharm US represents a repositioning of a legacy antimicrobial into a modern topical formulation.
Growth
As a pre-launch product, SEPTI-SOFT offers growth potential but limited current team size; career opportunities will expand post-approval if regulatory pathway succeeds.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on SEPTI-SOFT at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.